See also this year's filing and all EDGAR filings for this company.
PDF Report 0001374690_2018_Larimar_Therapeutics_Inc.pdf
Logs
warning | No LiabilitiesAndStockholdersEquity node found | input.sec.calculation_linkbase.edgar_model_mapping | {'lase_node': None, 'equity_node': None, 'partners_cap_node': None, 'nodes': "NodeView(('AssetsCurrent', 'Assets', 'PropertyPlantAndEquipmentNet', 'OtherAssetsNoncurrent', 'CashAndCashEquivalentsAtCarryingValue', 'AvailableForSaleSecuritiesDebtSecuritiesCurrent', 'TaxIncentiveReceivableCurrent', 'PrepaidExpenseAndOtherAssetsCurrent', 'LiabilitiesCurrent', 'Liabilities', 'LongTermNotesPayable', 'AccountsPayableCurrent', 'AccruedLiabilitiesCurrent', 'NotesPayableCurrent', 'PreferredStockValue', 'StockholdersEquity', 'CommonStockValue', 'AdditionalPaidInCapitalCommonStock', 'RetainedEarningsAccumulatedDeficit', 'AccumulatedOtherComprehensiveIncomeLossNetOfTax'))"} |
info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('0001374690')"} |
Graph
Absolute values for 0001374690, Larimar Therapeutics Inc.
xvar | xval | |
---|---|---|
0 | AssetsCurrent | 104,925,000 |
1 | IntangibleAssetsNetIncludingGoodwill | 0 |
2 | PropertyPlantAndEquipmentNet | 528,000 |
3 | remainder_Assets | 57,000 |
4 | LiabilitiesCurrent | 7,293,000 |
5 | LiabilitiesNoncurrent | 0 |
6 | remainder_Liabilities | 20,000,000 |
7 | CostOfGoodsAndServicesSold | 0 |
8 | SellingGeneralAndAdministrativeExpense | 12,160,000 |
9 | ResearchAndDevelopmentExpense | 40,839,000 |
10 | remainder_Expenses | 0 |
11 | remainder_Revenues | 0 |
12 | remainder_NetIncome | 971,000 |
13 | remainder_ComprehensiveNetIncome | 22,000 |
yvar | yval | |
---|---|---|
0 | Assets | 105,510,000 |
1 | Liabilities | 27,293,000 |
2 | Expenses | 52,999,000 |
3 | Revenues | 0 |
4 | StockholdersEquity | 78,217,000 |
5 | NetIncome | -52,028,000 |
6 | ComprehensiveNetIncome | -52,017,000 |
7 | BaseVar | 93,397,500 |
8 | EconomicCapitalRatio | 1.24 |